Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme

Must have received: surgery — initial

Surgically treated other than exclusive biopsy (complete or partial resection) of the GBM, for which adjuvant radiotherapy and chemotherapy is indicated

Cannot have received: any anti-cancer therapy

Pre-treated GBM

Cannot have received: exclusive biopsy or absence of initial surgery

Surgical treatment consisting in exclusive biopsy or absence of initial surgery

Cannot have received: prior malignancy

Prior malignancy

Cannot have received: radiation therapy, surgery or tumor embolization

radiation therapy, surgery or tumor embolization within 14 days prior to the first dose of pazoapnib

Cannot have received: chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy

chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy within 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of Pazopanib

Cannot have received: non-oncologic investigational drug

Administration of any non-oncologic investigational drug within 30 days or 5 half-lives whichever is longer prior to receiving the first dose of study treatment